Sensitizing Tumor Cells to Immune-Mediated Cytotoxicity

  • Anil Shanker
  • Thomas Sayers
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 601)


The molecular basis underlying tumor destruction in vivo by specific antitumor CD8+T cells remains unclear. We propose that the local production of certain tumor necrosis factor (TNF)-family members (death ligands) may be more important for tumor destruction in vivo than previously thought. Also, the apoptotic response of some tumor cells to the TNF-family member TRAIL can be augmented by the proteasome inhibitor bortezomib (Velcade). Thus, bortezomib may sensitize tumor cells to T cell-mediated cytotoxicity and could potentially improve the beneficial effects of immunotherapy.


Natural Killer Cell Tumor Antigen Adoptive Transfer Tumor Rejection Death Ligand 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Almasan, A. and Ashkenazi, A. (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337–348.CrossRefPubMedGoogle Scholar
  2. Coulie, P.G., Hanagiri, T. and Takenoyama, M. (2001) From tumor antigens to immunotherapy. Int. J. Clin. Oncol. 6, 163–170.CrossRefPubMedGoogle Scholar
  3. Ganten, T.M., Koschny, R., Haas, T.L., Sykora, J., Li-Weber, M., Herzer, K. and Walczak, H. (2005) Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42, 588–597.CrossRefPubMedGoogle Scholar
  4. Gattinoni, L., Powell, D.J., Rosenberg, S.A. and Restifo, N.P. (2006) Adoptove immuno-therapy for cancer: building on success. Nature 6, 383–393.Google Scholar
  5. Gillmore, R., Xue, S-A., Holler, A., Kaeda, J., Hadjiminas, D., Healy, V., Dina, R., Parry, S.C., Bellantuono, I., Ghani, Y., Coombes, R.C., Waxman, J. and Strauss, H.J. (2006) Detection of Wilms’ tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Human Cancer Biol. 12, 34–42.Google Scholar
  6. Gottschalk, S., Hislop, H.E. and Rooney, C.M. (2005) Adoptive immunotherapy of EBV-associated malignancies. Leuk. Lymphoma 46, 1–10.CrossRefPubMedGoogle Scholar
  7. Peng, L., Krauss, J.C., Plautz, G.E., Mukai, S., Shu, S. and Cohen, P.A. (2000) T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-γ g mechanisms that cannot be predicted from in vitro T cell characteristics. J. Immunol. 165, 7116–7124.PubMedGoogle Scholar
  8. Poehlein, C.H., Hu, H-M., Yamada, J., Assmann, I., Alvord, W.G., Urba, W.J. and Fox, B.A. (2003) TNF plays an essential role in tumor regression after adoptive transfer of perforin /IFN-γ gouble knockout effector T cells. J. Immunol. 170, 2004–2013.PubMedGoogle Scholar
  9. Qin, Z. and Blankenstein, T. (2000) CD4+T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ geceptor expression by nonhematopoetic cells. Immunity 12, 677–686.CrossRefPubMedGoogle Scholar
  10. Rosenberg, S.A., Yang, J.C. and Restifo, N.P. (2004) Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909–915.CrossRefPubMedGoogle Scholar
  11. Ryschich, E., Notzel, T., Hinz, U, Autschbach, F., Ferguson, J., Simon, I., Weitz, J., Frohlich, B., Klar, E., Buchler, M.W. and Schmidt, J. (2005) Control of T cell-mediated immune response by HLA class I in human pancreatic cancer. Clin. Cancer Res. 11, 498–504.PubMedGoogle Scholar
  12. Sayers, T.J., Brooks, A.D., Koh, C.Y., Ma, W., Seki, N., Raziuddin, A. Blazar, B.R., Zhang, X., Elliott, P.J. and Murphy, W.J. (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102, 303–310.CrossRefPubMedGoogle Scholar
  13. Sayers, T.J. and Murphy, W.J. (2006) Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol. Immunother. 55, 76–84.CrossRefPubMedGoogle Scholar
  14. Seki, N., Brooks, A.D., Carter, C.R.D., Back, T.C., Parsoneault, E.M., Smyth, M.J., Wiltrout, R.H. and Sayers, T.J. (2002) Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168, 3484–3492.PubMedGoogle Scholar
  15. Spiotto, M.T., Rowley, D.A. and Schrieber, H. (2004) Bystander elimination of antigen loss Variants in established tumors. Nat. Med. 10, 294–298.CrossRefPubMedGoogle Scholar
  16. Sun, K., Welniak, L., Panoskaltsis-Mortari, A., O’Shaughnessy, M.J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J.S., Blazar, B.R., Sayers, T.J. and Murphy, W.J. (2004) Inhibition of acute graft-versus-host disease with retention of graft -versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl. Acad. Sci. U.S.A. 101, 8120–8125.CrossRefPubMedGoogle Scholar
  17. Voskoboinik, I. and Trapani, J.A. (2006) Addressing the mysteries of perforin function. Immunol. and Cell Biol. 84, 66–71.CrossRefGoogle Scholar
  18. Winter, H., Hu, H-M., Urba, W.J. and Fox, B.A. (1999) Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (Apo-1L/CD95L). J. Immunol. 163, 4462–4472.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Cancer and Inflammation ProgramSAIC-Frederick Inc., NCI-FrederickFrederickUSA

Personalised recommendations